19,256 Shares in GeneDx Holdings Corp. (NASDAQ:WGS) Bought by Nia Impact Advisors LLC

Nia Impact Advisors LLC bought a new stake in GeneDx Holdings Corp. (NASDAQ:WGS - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 19,256 shares of the company's stock, valued at approximately $1,480,000. Nia Impact Advisors LLC owned approximately 0.07% of GeneDx at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of WGS. Barclays PLC increased its stake in shares of GeneDx by 346.3% in the third quarter. Barclays PLC now owns 18,921 shares of the company's stock worth $803,000 after buying an additional 14,681 shares during the period. Envestnet Asset Management Inc. bought a new stake in GeneDx in the 4th quarter worth $380,000. Prudential Financial Inc. purchased a new position in shares of GeneDx in the fourth quarter valued at about $7,938,000. Voya Investment Management LLC bought a new position in shares of GeneDx during the fourth quarter valued at about $292,000. Finally, JPMorgan Chase & Co. raised its stake in shares of GeneDx by 617.3% during the third quarter. JPMorgan Chase & Co. now owns 52,161 shares of the company's stock valued at $2,214,000 after acquiring an additional 44,889 shares during the last quarter. 61.72% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

WGS has been the topic of several recent analyst reports. Wells Fargo & Company cut their price target on shares of GeneDx from $105.00 to $78.00 and set an "equal weight" rating on the stock in a report on Thursday, May 1st. Jefferies Financial Group raised shares of GeneDx from a "hold" rating to a "buy" rating and set a $80.00 target price on the stock in a research note on Friday, May 9th. The Goldman Sachs Group increased their price target on shares of GeneDx from $70.00 to $80.00 and gave the stock a "neutral" rating in a research note on Wednesday, February 19th. TD Securities lowered their price objective on shares of GeneDx from $135.00 to $110.00 and set a "buy" rating for the company in a report on Thursday, May 1st. Finally, Guggenheim assumed coverage on GeneDx in a report on Thursday. They set a "buy" rating and a $88.00 target price on the stock. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $86.75.

Insider Transactions at GeneDx

In other GeneDx news, CEO Katherine Stueland sold 2,154 shares of GeneDx stock in a transaction dated Tuesday, April 29th. The stock was sold at an average price of $113.09, for a total value of $243,595.86. Following the transaction, the chief executive officer now owns 3,440 shares in the company, valued at $389,029.60. The trade was a 38.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Keith A. Meister acquired 100,000 shares of GeneDx stock in a transaction that occurred on Thursday, May 8th. The shares were purchased at an average price of $56.01 per share, with a total value of $5,601,000.00. Following the purchase, the director now owns 3,008,629 shares in the company, valued at $168,513,310.29. This represents a 3.44% increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have sold 139,390 shares of company stock worth $13,043,288. Insiders own 29.60% of the company's stock.

GeneDx Price Performance

Shares of NASDAQ:WGS traded up $4.70 during midday trading on Friday, reaching $68.31. 1,411,729 shares of the company were exchanged, compared to its average volume of 752,418. The stock has a market cap of $1.95 billion, a PE ratio of -34.85 and a beta of 1.96. The business's fifty day moving average is $87.10 and its two-hundred day moving average is $82.61. GeneDx Holdings Corp. has a one year low of $19.16 and a one year high of $117.75. The company has a current ratio of 2.40, a quick ratio of 2.27 and a debt-to-equity ratio of 0.25.

GeneDx (NASDAQ:WGS - Get Free Report) last issued its quarterly earnings data on Wednesday, April 30th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.17. GeneDx had a positive return on equity of 3.33% and a negative net margin of 17.12%. The business had revenue of $87.12 million for the quarter, compared to analysts' expectations of $79.90 million. As a group, analysts predict that GeneDx Holdings Corp. will post 0.97 earnings per share for the current year.

GeneDx Profile

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.